Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs iShares MSCI Hong Kong ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.62 (market cap $2.64B), while iShares MSCI Hong Kong ETF trades at $22.46. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | EWH | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $24.19 | $24.55 |
52-Week Low | $7.82 | $20.66 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
EWH, a US-listed stock tracking Hong Kong equities, trades at $22.465, down 1.47% over 24 hours. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The stock faces resistance at $23 and support at $22. Recent news highlights the Hang Seng Index's rebound, driven by technology sector gains, with EWH positioned to benefit from this momentum.
The outlook for EWH hinges on Hong Kong market performance, with potential upside from continued tech recovery and Asian market stability. Risks include regional volatility and macroeconomic pressures. Analysts show mixed sentiment, balancing technical bearishness with fundamental opportunities in the rebounding index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
